BioSpace News Archive

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, announced the commercial launch of its SARS-CoV-2 Total Ab test, a blood-based immunoassay kit to help determine if an individual has developed antibodies to SARS-CoV-2, the virus associated with COVID-19 disease.

Lenco Diagnostic Laboratories, one of NYC’s largest privately-owned full service reference laboratories, provides an update on COVID-19 testing and recently launched IgG and IgM serology testing to detect antibodies against COVID-19.

OrthoPediatrics Corp. announced that the Company is scheduled to release its first quarter 2020 financial results on Tuesday, May 5, 2020, after the market closes.

Investigator initiated study at Sweden’s Karolinska Institutet to test COVID-19 pneumonia patients with Unyvero HPN panel for bacterial co-infections

Arcutis Biotherapeutics, Inc. announced that it has enrolled the first patient in Phase 1/2b study of ARQ-252, a potent and highly selective topical small molecule inhibitor of janus kinase type 1, in adult patients with chronic hand eczema.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its wholly owned drug outsourcing facility, US Compounding Inc. (USC), has increased its product mix to provide additional drugs to assist in the ongoing fight against COVID-19.

A groundbreaking research project led by the Israeli Ministry of Defense (MOD) is currently underway at Afeka Tel-Aviv Academic College of Engineering to detect pre-diagnostic COVID-19 potential carriers using voice and speech processing

OncoSec Medical Incorporated (“OncoSec”) (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced pre-clinical data from a feasibility study of its visceral lesion applicator (VLA) electroporation device and APOLLO generator which were presented online at the Annual Meeting of the Society of Interventional Radiology (SIR).

Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that Bonus BioGroup (TASE: BONS.TA), a company in which Wize owns 8.9% of its equity securities, has initiated a preclinical study of its drug product candidate MesenCure,

twoXAR Pharmaceuticals, a company that discovers drugs with AI, today announced that two novel leads for the potential treatment of systemic lupus erythematosus (SLE), TXR-711 and TXR-712, demonstrated significant efficacy and excellent tolerability in preclinical studies.